Multimedia
Podcasts, videos, radio interviews, and tv appearances by New Zealand's Independent Research Organisations
Podcasts and audio
BRANZ: Clause H1 unpacked
13 November 2024: In this Master Builders Elevate podcast, Dr Chris Litten, General Manager of Research at BRANZ, unpacks the recent changes to Clause H1 of New Zealand's Building Code. Chris dives into the new energy efficiency standards, detailing updates in insulation, thermal performance, and ventilation requirements, and the practical challenges these pose for builders.
Cawthron: Fresh FM's Mending Our Desert in the Bay - Ep 3
28 October 2024: In this series of eight 30 minute programmes, Craig Prichard from the Cawthron Institute talks with scientists and marine professionals about the work they are doing, and how others can help around the Top of the South to mend what many regard as the watery desert in Te Tai-o-Aorere, Mohua, and the Sounds.
Cawthron: Fresh FM's Mending Our Desert in the Bay - Ep 2
21 October 2024: In this series of eight 30 minute programmes, Craig Prichard from the Cawthron Institute talks with scientists and marine professionals about the work they are doing. Cawthron Science Capability manager Chris Cornelisen discusses marine restoration options and monitoring.
>> more audio
Video and tv
2024 Rutherford Medal: Professor Richard Beasley
28 November 2024: Professor Richard Beasley CNZM FRSNZ has been awarded the Rutherford Medal for preeminent research by Royal Society Te Apārangi for revolutionising the treatment of asthma worldwide.
Malaghan: As easy as breathing - the future of vaccines
31 October 2024: PhD student Hannah Boswell is developing vaccines that can be inhaled, providing localised immunity in the lungs and airways and stopping respiratory viruses at the very point they enter the body.
Malaghan: CAR T-cell therapy, the battle of the blood cells
26 September 2024: CAR T-cell therapy uses modified blood cells to target and destroy cancerous blood cells. Dr Puja Paudel is researching ways to improve the effectiveness of CAR T-cell therapy for multiple myeloma, using a two-pronged attack to combat the high rates of relapse.